GTC BIOTHERAPEUTICS AND LEO PHARMA TO DEVELOP AND MARKET ATRYN IN EUROPE, THE MIDDLE EAST, AND CANADA

GTC Biotherapeutics, Inc. ("GTC", Nasdaq: GTCB) and LEO Pharma A/S ("LEO") have entered into a collaboration agreement to develop and market ATryn(R) for markets in Europe, the Middle East, and Canada. ATryn(R) is GTC's recombinant form of human antithrombin, a plasma protein with anticoagulant and anti-inflammatory properties. The agreement includes $73 million (USD) in potential milestone payments to GTC for meeting regulatory, clinical and sales goals.

Business Wire (http://www.biospace.com/news_story.aspx?StoryId=1245)